AUTHORS
Huiqiang Huang, MD, PhD, Ming Jiang, MD2, Jing Li3, Xu Ye, PhD4, Haiying Fu5, Yue Han, MD,PhD6, Hu Mao Gui7, XueJun Li8, Jian Tao9, Hua Wang, MD10, Xiaoxiao Wang, MD11, Pin Wu12, Feng Xiao13, Zhangjin Zheng14
AFFILIATIONS
1 Sun Yat-sen University Cancer Center, GuangDong, China
2 West China Hospital, Sichuan University, ChengDu, China
3 The First Affiliated Hospital of Guangxi Medical University, NanNing, China
4 The Second Affiliated Hospital of Guangzhou Medical University, NanNing, China
5 The Third People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, FuZhou, China
6 The First Affiliated Hospital of Soochow University, SuZhou, China
7 Anhui Provincial Cancer Hospital, HeFei, China
8 The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, NanNing, China
9 Nantong First People's Hospital, NanTong, China
10 Sun Yat-sen University Cancer Center, GuangDong, China
11 Sun Yat-sen University Cancer Center, GuangDong, China
12 Wuxi No.2 People's Hospital, WuXi, China
13 Hunan Provincial Hospital of Traditional Chinese Medicine, ChangSha, China
14 Fujian Medical University Union Hospital, FuZhou, China
ABSTRACT
Background
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of mature T-cell malignancies driven by constitutive hyperactivation of the JAK-STAT pathway. Golidocitinib, a highly selective JAK1 inhibitor, has demonstrated potent anti-lymphoma activity in systemic peripheral T-cell lymphoma (PTCL) in clinical trials; however, real-world evidence for single-agent Golidocitinib in relapsed/refractory (R/R) CTCL remains limited. This national, multicenter, retrospective real-world study presents an updated analysis aimed at characterizing clinical outcomes in heavily pretreated Chinese patients with R/R CTCL receiving Golidocitinib monotherapy.
Methods
We retrospectively screened 26 adult patients with pathologically confirmed R/R CTCL treated with Golidocitinib monotherapy, of whom 22 were enrolled in the Full Analysis Set (FAS). Four screened patients were excluded from efficacy assessments due to unevaluable target lesions (n=2) or loss to follow-up (n=2), leaving 20 patients in the Evaluable Analysis Set for response and progression-free survival (PFS) assessments. Baseline demographics, disease subtypes, lactate dehydrogenase (LDH) levels, CD30 expression status, concurrent hemophagocytic lymphohistiocytosis (HLH), prior systemic treatment lines and regimens, and treatment duration were summarized. Tumor assessment was performed by investigators following the International Society for Cutaneous Lymphomas (ISCL) and European Organization for Research and Treatment of Cancer (EORTC) consensus response criteria. The Clopper-Pearson exact method was used to calculate 95% confidence intervals (CIs) for objective response rate (ORR) and complete response rate (CRR), and the Kaplan-Meier method was employed to estimate investigator-assessed PFS and overall survival (OS). Treatment-related adverse events (TRAEs) were summarized descriptively.
Results
FAS Baseline Cohort (N=22): Median age was 41.5 years (range 22–85); 14 patients (63.6%) were female and 8 (36.4%) were male. Disease subtypes included subcutaneous panniculitis-like T-cell lymphoma (SPTCL; n=12, 54.5%), mycosis fungoides (MF; n=7, 31.8%), Sézary syndrome (SS; n=1, 4.5%), primary cutaneous TFH+ peripheral T-cell lymphoma (pcTFH-PTCL; n=1, 4.5%), and primary cutaneous extranodal NK/T-cell lymphoma (ENKTL; n=1, 4.5%). Concurrent HLH was observed in 3 patients (13.6%). Among evaluable patients (n=20), the median number of prior systemic regimens was 2 (range 1–5); 10 patients (45.5%) had received prior CHOP-based chemotherapy, and 13 (59.1%) had received prior chidamide. Median treatment duration among evaluable patients was 6.5 months (range 1.0–15.6).
Overall Efficacy (Evaluable Set, N=20): Best overall responses were CR in 7 patients (35.0%), PR in 11 (55.0%), SD in 1 (5.0%), and PD in 1 (5.0%), yielding an ORR of 90.0% (18/20; 95% CI: 68.3–98.8) and a CRR of 35.0% (7/20; 95% CI: 15.4–59.2).
SPTCL Subgroup (Evaluable N=10): All 10 patients responded, yielding an ORR of 100.0% (95% CI: 69.2–100.0); among these, 7 patients (70.0%) achieved CR (95% CI: 34.8–93.3) and 3 (30.0%) achieved PR.
MF Subgroup (Evaluable N=7): ORR was 71.4% (95% CI: 29.0–96.3), with 5 PR (71.4%), 1 SD (14.3%), and 1 PD (14.3%).
Survival Endpoints: The 18-month PFS rate was 95.0% (95% CI: 69.5–99.3). With a median follow-up of 11.8 months (range 3.0–24.7), median OS was not reached.
Safety: TRAEs were predominantly hematologic toxicities and infections, which were mild and manageable with dose modification, supportive care, or temporary drug interruption. No treatment-related deaths were observed.
Conclusion
This updated real-world analysis with a larger sample size confirms that single-agent Golidocitinib achieves robust and durable antitumor activity, with an outstanding long-term PFS benefit and favorable tolerability in heavily pretreated patients with R/R CTCL. Notably, efficacy was markedly superior in the SPTCL subtype, with a 100% ORR and 70% CR rate. The overall 18-month PFS rate of 95.0% supports Golidocitinib as a preferred therapeutic option for R/R CTCL, particularly for SPTCL. Prospective clinical trials are warranted to further validate these real-world observations.
DISCLOSURES
Huiqiang Huang, MD, PhD: No relevant conflicts of interest to declare.